TABLE 3.
Efficacy of chemotherapy, TKIs + chemotherapy and TKIs + ICIs in patients with advanced or metastatic gastric cancer.
| Parameter | Best response | ORR | P | DCR | P | Median PFS (95%CI) | P | Median OS (95%CI) | P | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CR | PR | SD | PD | |||||||||
| Total | 0 | 29 | 75 | 58 | 17.9 (29/162) | — | 64.2% (104/162) | — | 3.0 (2.7–3.3) | — | 6.0 (5.0–7.0) | — |
| Treatment programs | 0.924 | 0.029 | 0.010 | 0.026 | ||||||||
| Chemotherapy | 0 | 10 | 23 | 28 | 16.4 (10/61) | — | 54.1 (33/61) | — | 2.8 (2.1–3.5) | — | 5.8 (5.5–6.1) | — |
| TKIs + chemotherapy | 0 | 9 | 28 | 10 | 19.1 (9/47) | 0.709 a | 78.7 (37/47) | 0.008 a | 3.3 (2.3–4.3) | 0.001 a | 8.0 (4.0–12.0) | 0.005 a |
| TKIs + ICIs | 0 | 10 | 24 | 20 | 18.5 (10/54) | 0.764 a | 63.0 (34/54) | 0.336 a | 3.0 (2.4–3.6) | 0.051 | 5.2 (3.4–7.0) | 0.260 |
| Type in TKIs + chem | 0.132 | 0.703 | 0.129 | 0.764 | ||||||||
| Apatinib + chem | 0 | 7 | 14 | 5 | 26.9 (7/26) | 80.8 (21/26) | 4.2 (2.3–6.1) | 8.0 (1.8–14.2) | ||||
| Anlotinib + chem | 0 | 2 | 14 | 5 | 9.5 (2/21) | 76.2 (16/21) | 3.2 (2.9–3.5) | 7.5 (3.0–12.0) | ||||
| Type in TKIs + ICIs | 0.658 | 0.477 | 0.062 | 0.216 | ||||||||
| Apatinib + ICIs | 0 | 4 | 13 | 8 | 16.0 (4/25) | 68.0 (17/25) | 2.4 (1.7–3.1) | 6.0 (3.2–8.8) | ||||
| Anlotinib + ICIs | 0 | 6 | 11 | 12 | 20.7 (6/29) | 58.6 (17/29) | 3.0 (0.4–5.6) | 5.0 (2.4–7.6) | ||||
Abbreviations: CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, overall response rate; DCR, disease control rate; PFS, progression free survival; OS, overall survival; TKI, tyrosine kinase inhibitors; ICIs, immune checkpoint inhibitors.
a
compared with chemotherapy group.